Coverage of Prescription Drugs for Pain:
HB 1093 would create two new sections of Florida Statutes to require more neutral Medicaid coverage rules for pain medications. One section applies to the state Medicaid program, and the other applies to Medicaid managed care plans. In both settings, the bill defines a “nonopioid pain drug” as an FDA-approved nonopioid medication for pain treatment or management and directs coverage policies so that these drugs are not disadvantaged or discouraged relative to opioid or narcotic pain drugs.
The bill specifically prohibits certain formulary and utilization practices. For example, a nonopioid pain drug could not be placed on a nonpreferred tier if an opioid or narcotic pain drug is preferred, and it could not face more restrictive prior authorization, step therapy, or other utilization controls than the least restrictive controls applied to comparable opioid or narcotic drugs for the same condition. The act would take effect July 1, 2025.
HB 1093 would amend Florida’s Medicaid statutes by adding new coverage requirements for pain medications in both fee-for-service Medicaid and Medicaid managed care. It would constrain the Agency for Health Care Administration and managed care plans from using formulary placement or utilization management in ways that favor opioids over FDA-approved nonopioid pain drugs, potentially affecting preferred drug lists, prior authorization policies, and step-therapy rules for covered pain treatments.
The bill’s apparent policy direction is favorable toward expanding access to nonopioid pain treatments and reducing barriers that may steer patients toward opioids. However, there is no recorded committee debate or vote history in the provided materials, and the bill died in the Health Care Facilities & Systems Subcommittee, indicating it did not advance despite its stated public-health rationale.
The main policy issue is how much discretion Medicaid and managed care plans should retain in managing drug coverage. Supporters would likely favor the bill as an opioid-sparing measure that promotes safer pain management and fairer access to nonopioid alternatives. Potential concerns could come from administrators or plans worried about limits on formulary management, increased costs, or reduced flexibility in applying prior authorization and step-therapy controls. No specific objections are documented in the provided record.